Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

CANF has been the topic of several other reports. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $1.55 on Friday. The stock has a 50 day moving average price of $1.73 and a 200 day moving average price of $2.27. Can-Fite BioPharma has a one year low of $1.29 and a one year high of $4.69. The stock has a market capitalization of $5.49 million, a price-to-earnings ratio of -0.87 and a beta of 1.36.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC lifted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission. 21.00% of the stock is currently owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.